Medicines without prospectus

Medicines without prospectus

Prospectus or medicines leaflet delivered with drugs contain adequate information for the use of medicines prescribed by your doctor or pharmacist. These data made available to patients are mandated by the state, manufacturers and distributors.

It is also recommended to read carefully. However, health insurance for certain packages without requiring thumbnail presentation of the prospectus or leaflet of the drug as proof of purchase in order to process your refund. Those leaflets are usually an act which frequently engages practitioners and pharmacists, and without notice patients are at risk.

Indeed, prescribers and consumers need different types of information to ensure a safe and effective use of medicines. Indeed, the references in the packaging or leaflets are a valuable source of information and are the result of years of research and clinical trials. Apart from the International Nonproprietary Name (INN) of each active substance, these notices include pharmacological data with a brief description of pharmacological effects and mode of action and clinical information. In addition to the prescription of the doctor, the instruction guides also include therapeutic indications in this case the average dose limit and in the adult and child spacing of doses and the average duration of treatment and precautions for use in special situations: renal, hepatic, cardiac or nutritional, for example, requiring a decrease or increase the dosages.

But when it comes to contraindications related to the use of the drug, reading the prospectus is strongly recommended. Indeed, the precautions and warnings, side effects and drug interactions or the use of specific antidotes for overdoses represent information that can be vital in some cases.
However, chemist may sometimes and unconsciously expose the patient to a few dangers, when he removes out from the pack this valuable document for the purposes of health insurance for possible reimbursement. For that vital purpose the authorities are forcing pharmaceutical companies to provide such a document with their products to patients and citizens, it is quite logical to consider the risks associated with removing references to their packaging.

It is perhaps time to think about generalizing the thumbnails to all drugs so that the leaflet or prospectus which is specifically for patients remains available to them throughout the treatment period.